Evidence map›Paper›PMID 32236803›Full record

ArticleBiomolecular NMR assignments2020

Michelangelo Marasco, John P Kirkpatrick, Teresa Carlomagno

Open access · hybridAbstract read
In one paragraph

Article in Biomolecular NMR assignments, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. NMR Methods to Study the Dynamics of SH2 Domain-Phosphopeptide Complexes.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michelangelo MarascoCenter for Biomolecular Drug Design and Institute of Organic Chemistry, Leibniz University Hannover, Schneiderberg 38, 30167, Hannover, Germany.
John P KirkpatrickCenter for Biomolecular Drug Design and Institute of Organic Chemistry, Leibniz University Hannover, Schneiderberg 38, 30167, Hannover, Germany.
Teresa CarlomagnoCenter for Biomolecular Drug Design and Institute of Organic Chemistry, Leibniz University Hannover, Schneiderberg 38, 30167, Hannover, Germany. teresa.carlomagno@oci.uni-hannover.de.ORCID 0000-0002-2437-2760
Leibniz University Hannover · DE

Funding

Deutsche Forschungsgemeinschaft CA294/20-1
6 · The paper itself

Abstract

Inhibition of immune checkpoint receptor Programmed Death-1 (PD-1) via monoclonal antibodies is an established anticancer immunotherapeutic approach. This treatment has been largely successful; however, its high cost demands equally effective, more affordable alternatives. To date, the development of drugs targeting downstream players in the PD-1-dependent signaling pathway has been hampered by our poor understanding of the molecular details of the intermolecular interactions involved in the pathway. Activation of PD-1 leads to phosphorylation of two signaling motifs located in its cytoplasmic domain, the immune tyrosine inhibitory motif (ITIM) and immune tyrosine switch motif (ITSM), which recruit and activate protein tyrosine phosphatase SHP2. This interaction is mediated by the two Src homology 2 (SH2) domains of SHP2, termed N-SH2 and C-SH2, which recognize phosphotyrosines pY223 and pY248 of ITIM and ITSM, respectively. SHP2 then propagates the inhibitory signal, ultimately leading to suppression of T cell functionality. In order to facilitate mechanistic structural studies of this signaling pathway, we report the resonance assignments of the complexes formed by the signaling motifs of PD-1 and the SH2 domains of SHP2.

Indexed as

Carbon-13 Magnetic Resonance SpectroscopyProton Magnetic Resonance Spectroscopysrc Homology DomainsAmino Acid MotifsHumansNitrogen IsotopesNuclear Magnetic Resonance, BiomolecularProgrammed Cell Death 1 ReceptorProtein Tyrosine Phosphatase, Non-Receptor Type 11TyrosineNitrogen-15Nitrogen IsotopesProgrammed Cell Death 1 ReceptorProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanTyrosineImmunotherapyPD-1SH2 domainsSHP2

Identifiers

PMID32236803
PMCPMC7462904
OpenAlexW3014094962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.